Marker Therapeutics financials
$1.10−2.22%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $6.6M | $3.3M | $3.5M | $1.2M | $466.8K | $213.2K | $206.0K |
| Gross profit | $3.5M | $6.6M | $3.3M | $3.5M | $1.2M | $466.8K | $213.2K | $206.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$12.9M | -$11.1M | -$14.6M | -$19.8M | -$39.5M | -$28.9M | -$22.5M | -$148.2M |
| Net income | -$12.2M | -$10.7M | -$8.2M | -$29.9M | -$41.9M | -$28.7M | -$21.4M | -$148.0M |
| Net margin | −343.0% | −162.8% | −248.8% | −851.9% | −3372.7% | −6149.7% | −10050.9% | −71826.3% |
| Diluted EPS | $-0.79 | $-1.19 | $-0.94 | $-3.58 | $-5.47 | $-6.10 | $-4.70 | $-77.50 |
| EBITDA | -$12.4M | -$11.1M | -$14.6M | -$19.8M | -$36.3M | -$27.8M | -$22.2M | -$148.2M |
| Operating cash flow | -$12.0M | -$10.9M | -$16.4M | -$27.0M | -$27.3M | -$20.0M | -$18.3M | -$14.5M |
| Free cash flow | -$12.0M | -$10.9M | -$16.4M | -$27.0M | -$30.4M | -$29.3M | -$18.7M | -$14.6M |
| Diluted shares | 15.3M | 9.0M | 8.8M | 8.4M | 7.7M | 4.7M | 4.6M | 1.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $16.1M | $19.2M | $15.1M | $11.8M | $42.4M | $21.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $19.1M | $22.0M | $17.1M | $34.4M | $68.1M | $45.6M |
| Total liabilities | $2.3M | $3.5M | $3.1M | $14.8M | $24.1M | $18.3M |
| Shareholders' equity | $16.8M | $18.6M | $14.1M | $19.6M | $44.0M | $27.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology